PTAB Axes 2 Patents On Insulin Drug Lantus
The Patent Trial and Appeal Board on Wednesday invalidated two Sanofi-Aventis Deutschland GmbH patents for the insulin medication Lantus, while calling evidence of the success of the multibillion-dollar drug "weak" because...To view the full article, register now.
Already a subscriber? Click here to view full article